Drug Trial Radar · NCT01306890
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,976
Actual
Start
Jan 27, 2011
Primary completion
Jan 17, 2017
Study completion Jan 17, 2017
Sponsor
- Lead sponsor
- DendreonIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2011
Design
- Study type
- Observational
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Conditions
- Advanced Prostate Cancer
- Prostatic Neoplasms
Interventions
sipuleucel-TBiological
Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Further Quantify the Risk of Cerebrovascular Events Following Sipuleucel-T Therapy for All SubjectsTime frame: Every 3 months for a minimum of 3 years
Locations
333 sites in 1 country. Site status is shown where the registry gives one.
Birmingham Hematology and Oncology Associates, LLC
Bessemer, Alabama
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama
Clearview Cancer Institute
Huntsville, Alabama
Ironwood Cancer and Research
Chandler, Arizona
Palo Verde Cancer Specialists
Glendale, Arizona
Weatern Regional Medical Center / Cancer Treatment Centers of America
Goodyear, Arizona
21st Century Oncology
Scottsdale, Arizona
Pinnacle Oncology Hematology, Oncology Research Associates, PLLC
Scottsdale, Arizona
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona
El Dorado Research
Tucson, Arizona
Urological Associates of Southern Arizona, P.C.
Tucson, Arizona
Little Rock Hematology Oncology: A Division of CARTI
Little Rock, Arkansas
South County Hematology/Oncology
Chula Vista, California
Wilshire Oncology Medical Group, Inc.
Corona, California
Urology Specialists of Southern California
Encino, California
Robert A. Moss, M.D., F.A.C.P., Inc
Fountain Valley, California
Pacific Shores Medical Group
Glendale, California
Wilshire Oncology Medical Group, Inc.
Glendora, California
Pacific Shores Medical Group
Huntington Beach, California
UCSD Medical Center - La Jolla
La Jolla, California
UCSD Moores Cancer Center
La Jolla, California
Moores UCSD Cancer Center
La Jolla, California
Cancer Center Oncology Medical Group
La Mesa, California
Wilshire Oncology Medical Group, Inc.
La Verne, California
Pacific Shores Medical Group
Long Beach, California
Pacific Shores Medical Group
Los Alamitos, California
UCLA Institute of Urologic Oncology, UCLA Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
Tower Urology
Los Angeles, California
Prostate Oncology Speciality Inc.
Marina del Rey, California
Tri Valley Urology Medical Group
Murrieta, California
North County Oncology Medical Group, Inc.
Oceanside, California
Hematology-Oncology Medical Group of Orange County, Inc.
Orange, California
Medical Oncology Care Associates (MOCA)
Orange, California
The Center for Cancer Prevention and Treatment, St. Joseph Hospital
Orange, California
Showing 40 of 333 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.